v3.26.1
Out-Licensing Agreements (Details)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Feb. 28, 2022
USD ($)
item
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Sep. 30, 2022
USD ($)
item
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Dec. 31, 2024
USD ($)
Collaborative agreements              
Revenue   $ 243,600 $ 156,797   $ 457,866 $ 294,582  
Territory License - ARCALYST              
Collaborative agreements              
Upfront payments received $ 12,000            
Addition to transaction price         20,000   $ 20,000
Number of performance obligations in an agreement | item 1            
Term of agreement for royalty payments 12 years            
Territory License - ARCALYST | Maximum              
Collaborative agreements              
Payments to be received by the company upon the achievement of specified development, regulatory and sales milestones         50,000    
Territory License - ARCALYST | Location, Statement of Financial Position, Activity, Accrual [Axis]: us-gaap:ContractWithCustomerLiabilityNoncurrent              
Collaborative agreements              
Transaction price         31,811    
Territory License - ARCALYST | License and collaboration revenue              
Collaborative agreements              
Revenue   0 0   0 0  
Worldwide License - Vixarelimab              
Collaborative agreements              
Number of performance obligations in an agreement | item       4      
Payments to be received by the company upon the achievement of specified development, regulatory and sales milestones       $ 600,000 570,000    
Worldwide License - Vixarelimab | License and collaboration revenue              
Collaborative agreements              
Revenue   $ 0 $ 0   $ 0 $ 0